Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Asahi Kasei Pharma to Promote Elcitonin for Pain in Osteoporosis
April 5, 2004
- BULLETIN
April 5, 2004
- Midterm Management Plan for Mediceo Group Announced
April 5, 2004
- PRESS SEMINAR
April 5, 2004
- Contract Mfg Now Accounts for Half of Sales: Nipro Pharma
April 5, 2004
- JMA Announces Report on Medical Practices, Bioethics
April 5, 2004
- Drug Organization Investment Project Receives Qualified Praise from Participants: JPMA Survey
April 5, 2004
- OTC NEWS IN BRIEF
April 5, 2004
- BUSINESS NEWS IN BRIEF
April 5, 2004
- Iryo Proverbs Reveal Japanese Spirit (18)
April 5, 2004
- Janssen Pharmaceutical Aims at Sales of \100 Bil. in 2006: Mr Sekiguchi
April 5, 2004
- DIAGNOSTIC NEWS IN BRIEF
April 5, 2004
- CORPORATE ROUNDUP NEWS IN BRIEF
April 5, 2004
- Kyowa Hakko to License "Potelligent" Technology to US Companies
April 5, 2004
- Somusho Asks Korosho to Simplify Approval Modification Procedure
April 5, 2004
- BULLETIN
April 5, 2004
- Off-label Use of Drugs in Children Reported: Korosho Panel
April 5, 2004
- REGULATORY NEWS IN BRIEF
April 5, 2004
- Generics' Share Up to 6.3% on Purchase Price Basis at National Hospitals
April 5, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
April 5, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…